Treatment of symptomatic uterine leiomyoma with letrozole

Bilgin Gurates, Cem Parmaksiz, Gokhan Kilic, Husnu Celik, Selahattin Kumru, Mehmet Simsek

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Uterine leiomyomas are the most common benign tumours of the female genital tract, often necessitating hysterectomy. The most common symptoms are dysmenorrhoea, menorrhagia, infertility and abortion. Ovarian hormones seem to play an essential role in pathogenesis, and deprivation of ovarian oestrogen causes leiomyomas to shrink significantly. The purpose of this study was to evaluate the effects of the non-steroidal aromatase inhibitor letrozole on uterine leiomyomas and on bone metabolism. A prospective, open clinical trial was conducted in a university-based hospital. Sixteen premenopausal women with symptomatic uterine leiomyomas were treated with letrozole 5 mg/day orally for 3 months. The main outcome measures of uterine and uterine leiomyoma sizes, serum FSH, LH, oestradiol concentrations, ovarian volumes and myoma-related symptoms were noted at baselines and once a month during treatment. Lumbar spine bone mineral density and biochemical markers of bone metabolism were studied at the beginning and at the end of 3 months. Letrozole significantly decreased uterine leiomyoma sizes (P <0.01) and promptly benefited women with heavy menstrual bleeding associated with leiomyomas without changing bone mineral density. Aromatase inhibitors may represent a new generation of medications for the treatment of leiomyoma and associated symptoms. Larger clinical trials are needed, however, to fully evaluate their safety and efficacy.

Original languageEnglish (US)
Pages (from-to)569-574
Number of pages6
JournalReproductive BioMedicine Online
Volume17
Issue number4
StatePublished - Oct 2008
Externally publishedYes

Fingerprint

letrozole
Leiomyoma
Aromatase Inhibitors
Therapeutics
Bone Density
Clinical Trials
Menorrhagia
Bone and Bones
Myoma
Dysmenorrhea
Hysterectomy

Keywords

  • Aromatase inhibitor
  • Bone density/metabolism
  • Myoma
  • Oestrogen
  • Uterine leiomyomata

ASJC Scopus subject areas

  • Reproductive Medicine
  • Developmental Biology

Cite this

Gurates, B., Parmaksiz, C., Kilic, G., Celik, H., Kumru, S., & Simsek, M. (2008). Treatment of symptomatic uterine leiomyoma with letrozole. Reproductive BioMedicine Online, 17(4), 569-574.

Treatment of symptomatic uterine leiomyoma with letrozole. / Gurates, Bilgin; Parmaksiz, Cem; Kilic, Gokhan; Celik, Husnu; Kumru, Selahattin; Simsek, Mehmet.

In: Reproductive BioMedicine Online, Vol. 17, No. 4, 10.2008, p. 569-574.

Research output: Contribution to journalArticle

Gurates, B, Parmaksiz, C, Kilic, G, Celik, H, Kumru, S & Simsek, M 2008, 'Treatment of symptomatic uterine leiomyoma with letrozole', Reproductive BioMedicine Online, vol. 17, no. 4, pp. 569-574.
Gurates B, Parmaksiz C, Kilic G, Celik H, Kumru S, Simsek M. Treatment of symptomatic uterine leiomyoma with letrozole. Reproductive BioMedicine Online. 2008 Oct;17(4):569-574.
Gurates, Bilgin ; Parmaksiz, Cem ; Kilic, Gokhan ; Celik, Husnu ; Kumru, Selahattin ; Simsek, Mehmet. / Treatment of symptomatic uterine leiomyoma with letrozole. In: Reproductive BioMedicine Online. 2008 ; Vol. 17, No. 4. pp. 569-574.
@article{ba13aef89cff4a20ac3fba60ec8e812d,
title = "Treatment of symptomatic uterine leiomyoma with letrozole",
abstract = "Uterine leiomyomas are the most common benign tumours of the female genital tract, often necessitating hysterectomy. The most common symptoms are dysmenorrhoea, menorrhagia, infertility and abortion. Ovarian hormones seem to play an essential role in pathogenesis, and deprivation of ovarian oestrogen causes leiomyomas to shrink significantly. The purpose of this study was to evaluate the effects of the non-steroidal aromatase inhibitor letrozole on uterine leiomyomas and on bone metabolism. A prospective, open clinical trial was conducted in a university-based hospital. Sixteen premenopausal women with symptomatic uterine leiomyomas were treated with letrozole 5 mg/day orally for 3 months. The main outcome measures of uterine and uterine leiomyoma sizes, serum FSH, LH, oestradiol concentrations, ovarian volumes and myoma-related symptoms were noted at baselines and once a month during treatment. Lumbar spine bone mineral density and biochemical markers of bone metabolism were studied at the beginning and at the end of 3 months. Letrozole significantly decreased uterine leiomyoma sizes (P <0.01) and promptly benefited women with heavy menstrual bleeding associated with leiomyomas without changing bone mineral density. Aromatase inhibitors may represent a new generation of medications for the treatment of leiomyoma and associated symptoms. Larger clinical trials are needed, however, to fully evaluate their safety and efficacy.",
keywords = "Aromatase inhibitor, Bone density/metabolism, Myoma, Oestrogen, Uterine leiomyomata",
author = "Bilgin Gurates and Cem Parmaksiz and Gokhan Kilic and Husnu Celik and Selahattin Kumru and Mehmet Simsek",
year = "2008",
month = "10",
language = "English (US)",
volume = "17",
pages = "569--574",
journal = "Reproductive BioMedicine Online",
issn = "1472-6483",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Treatment of symptomatic uterine leiomyoma with letrozole

AU - Gurates, Bilgin

AU - Parmaksiz, Cem

AU - Kilic, Gokhan

AU - Celik, Husnu

AU - Kumru, Selahattin

AU - Simsek, Mehmet

PY - 2008/10

Y1 - 2008/10

N2 - Uterine leiomyomas are the most common benign tumours of the female genital tract, often necessitating hysterectomy. The most common symptoms are dysmenorrhoea, menorrhagia, infertility and abortion. Ovarian hormones seem to play an essential role in pathogenesis, and deprivation of ovarian oestrogen causes leiomyomas to shrink significantly. The purpose of this study was to evaluate the effects of the non-steroidal aromatase inhibitor letrozole on uterine leiomyomas and on bone metabolism. A prospective, open clinical trial was conducted in a university-based hospital. Sixteen premenopausal women with symptomatic uterine leiomyomas were treated with letrozole 5 mg/day orally for 3 months. The main outcome measures of uterine and uterine leiomyoma sizes, serum FSH, LH, oestradiol concentrations, ovarian volumes and myoma-related symptoms were noted at baselines and once a month during treatment. Lumbar spine bone mineral density and biochemical markers of bone metabolism were studied at the beginning and at the end of 3 months. Letrozole significantly decreased uterine leiomyoma sizes (P <0.01) and promptly benefited women with heavy menstrual bleeding associated with leiomyomas without changing bone mineral density. Aromatase inhibitors may represent a new generation of medications for the treatment of leiomyoma and associated symptoms. Larger clinical trials are needed, however, to fully evaluate their safety and efficacy.

AB - Uterine leiomyomas are the most common benign tumours of the female genital tract, often necessitating hysterectomy. The most common symptoms are dysmenorrhoea, menorrhagia, infertility and abortion. Ovarian hormones seem to play an essential role in pathogenesis, and deprivation of ovarian oestrogen causes leiomyomas to shrink significantly. The purpose of this study was to evaluate the effects of the non-steroidal aromatase inhibitor letrozole on uterine leiomyomas and on bone metabolism. A prospective, open clinical trial was conducted in a university-based hospital. Sixteen premenopausal women with symptomatic uterine leiomyomas were treated with letrozole 5 mg/day orally for 3 months. The main outcome measures of uterine and uterine leiomyoma sizes, serum FSH, LH, oestradiol concentrations, ovarian volumes and myoma-related symptoms were noted at baselines and once a month during treatment. Lumbar spine bone mineral density and biochemical markers of bone metabolism were studied at the beginning and at the end of 3 months. Letrozole significantly decreased uterine leiomyoma sizes (P <0.01) and promptly benefited women with heavy menstrual bleeding associated with leiomyomas without changing bone mineral density. Aromatase inhibitors may represent a new generation of medications for the treatment of leiomyoma and associated symptoms. Larger clinical trials are needed, however, to fully evaluate their safety and efficacy.

KW - Aromatase inhibitor

KW - Bone density/metabolism

KW - Myoma

KW - Oestrogen

KW - Uterine leiomyomata

UR - http://www.scopus.com/inward/record.url?scp=54449086371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54449086371&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 569

EP - 574

JO - Reproductive BioMedicine Online

JF - Reproductive BioMedicine Online

SN - 1472-6483

IS - 4

ER -